Top 50 Cell Line Development in Africa

NewForm Foods utilizes cellular agriculture technology and proprietary bioprocessing to enable food producers and retailers to efficiently scale the production of cultivated meat and sustainable food products. By reducing capital and operational costs, the platform addresses the need for environmentally friendly food systems that do not compromise on taste or animal welfare.

The startup develops a synthetic biology plant architecture that utilizes proprietary hyper-integration algorithms and precision fermentation to create customized modular plant systems at scale. This approach significantly reduces the time and costs associated with bringing synthetic biology products to market, addressing inefficiencies in traditional biomanufacturing processes.

Cape Bio Pharms produces recombinant proteins using Nicotiana benthamiana plants, which enhances yield and lowers production costs compared to conventional methods. This technology provides a scalable solution for efficient protein production in biopharmaceutical applications.

Uses soil and seed science combined with AI-driven digital tools to provide smallholder farmers in Africa with personalized soil health insights, improved seed loans, and direct-to-consumer market access. This approach increases crop yields, reduces post-harvest losses, and transforms farmers into agribusiness owners while promoting sustainable agricultural practices.

Molmir is a biotech company that utilizes sensing technology to research and develop treatments for intractable diseases. Their approach focuses on identifying and targeting specific biological markers, enabling more effective therapeutic interventions for conditions that currently lack viable treatment options.

Hyperion FoodTech utilizes regenerative medicine and gene therapy technologies to develop sustainable food ingredients that enhance nutritional profiles and reduce reliance on traditional agriculture. This approach addresses food security challenges by providing alternative sources of essential nutrients while minimizing environmental impact.

Synteny develops frontier AI, called MANIFOLD™, to address the challenge of molecular recognition in biology. The platform unifies sequence, structure, and physics data to learn the fundamental laws governing biological cognition. This capability transforms molecular recognition from an intractable problem into programmable biology aimed at decoding biology to end disease.

The startup is creating Africa's first digital biobank by integrating genetic testing with encryption technology to establish secure bio-identities. This approach enables users to manage, interpret, and safeguard their genetic information, addressing the need for privacy and control over personal genetic data.

DIANA Biotechnologies develops RT-PCR diagnostic kits and monoclonal antibodies, utilizing proprietary DIANA technology to enhance clinical diagnostics and drug discovery processes. The company addresses the need for reliable and efficient testing solutions in respiratory virus detection and supports the development of targeted therapies in the biotech sector.

Aelius Biotech develops integrated in vitro gastrointestinal models that simulate digestion, mucus permeation, and epithelial absorption to facilitate the development of orally delivered products. Their technology enables companies to make data-driven decisions early in the product development process, reducing risks and costs associated with traditional testing methods.

The startup is developing a molecular simulation platform that utilizes advanced computational techniques to enhance the drug discovery process. This technology enables researchers to predict molecular interactions more accurately, significantly reducing the time and cost associated with bringing new therapeutics to market.

This startup provides an AI-powered platform with advanced machine learning tools and algorithms to accelerate biomolecular design. It enables biotech companies to innovate faster and develop novel therapeutics by streamlining the design process.

The startup provides aquaculture health management technologies that include diagnostic tools and therapeutic solutions to enhance fish farm health and productivity. By leveraging biotechnology, the company aims to improve annual yields and ensure long-term food security for aquaculture farmers globally.

Immobazyme produces recombinant growth factors for cellular agriculture using a modular protein expression system, enabling scalable and cost-effective solutions that eliminate the need for animal-derived products. The company also offers contract research services focused on waste valorization and downstream processing optimization, enhancing product efficiency and sustainability for various industries.

GitLife Biotech provides a version control system for synthetic biology through its CellRepo™ platform, which organizes and secures data generated during strain engineering processes. This technology enhances traceability and ownership of biological assets by linking digital records to unique DNA Genosignatures®, ensuring precise documentation and compliance in genetic engineering.

MiGenTra develops biosimilars, cell and gene therapies, and vaccines to enhance access to high-quality medicines in Egypt, the Middle East, and Africa. By leveraging local manufacturing capabilities and expertise from ProBioGen and Minapharm Pharmaceuticals, the company addresses the need for affordable healthcare solutions in the region.

The startup operates a cell biobank that provides a diverse range of African species cell lines for the foodtech and biomedical sectors. This resource enables the development of sustainable biotechnological solutions that enhance biodiversity and improve global food security.

FC Renew develops a low-cost restoration technology for degraded hydrogen fuel cells, utilizing advanced electrochemical methods to enhance their efficiency and extend their operational lifespan. This technology directly addresses the issue of fuel cell degradation, which significantly limits the performance and viability of hydrogen energy systems.

This company develops biological technology for efficient and scalable recombinant protein production. Their platform enables clients to produce high-quality, cost-effective recombinant proteins locally, streamlining the manufacturing process for various applications.

Aspyre Foods produces scalable, animal-free casein protein, enabling superior texture, melt, and stretch in cheese and enhanced functionality in sports nutrition. The company also extracts high-purity Rubisco from duckweed, offering a clean-label, allergen-friendly protein for meat alternatives and beverages. Their platform leverages controlled duckweed cultivation for cost-effective, consistent, and sustainable functional protein ingredient supply.

Bixbio is a bioinformatics company that develops analytical tools to harness Africa's vast and underutilized genetic diversity for drug discovery. By providing insights into this genetic data, Bixbio aims to enhance the efficacy and accessibility of pharmaceuticals globally.

This company develops gene therapies for inherited retinal diseases, delivering normal gene copies to retinal cells to correct deficits caused by mutations. Their approach aims to either replace or silence disease-causing genes, potentially restoring vision for patients with genetic blindness.

The startup develops mycelium-based fermentation technology to produce natural, bio-based ingredients for the food and beverage sector. This approach replaces environmentally harmful production methods with sustainable alternatives, reducing waste and promoting a circular economy.

The startup is developing epigenetic therapies using clinically validated p38 MAP kinase inhibitors and other small molecules to provide functional cures for patients with Friedreich's Ataxia. This approach aims to advance treatment options in the healthcare industry, similar to breakthroughs achieved in Cystic Fibrosis.

This company designs and manufactures high-performance battery systems specifically for high power applications. They also develop integration solutions for electric and hybrid propulsion systems. Additionally, the company offers design and implementation services for broader mobility and energy systems.

Bioada utilizes AI-driven biomarker and drug discovery techniques to enhance early disease detection and develop personalized treatment plans. By leveraging advanced algorithms, the company accelerates the identification of novel biomarkers and optimizes drug formulations, improving patient outcomes in precision medicine.

ESPDx is developing scalable liquid-biopsy tests that utilize disease-specific biomarkers from Extracellular Vesicles in blood and saliva to enable early and accurate diagnosis of Lewy Body Dementia and Parkinson’s Disease. This technology addresses the limitations of current diagnostic methods, which are often invasive and costly, by providing a minimally invasive alternative that enhances patient management and supports clinical trial patient stratification.